NBIX News and Press, Neurocrine Biosciences Inc. From 10/19/22

Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference PR Newswire SAN DIEGO , Oct. 19, 2022 /PRNewswire/ -- Neurocrine Biosciences, I...

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results PR Newswire Conference Call and Webcast Scheduled for Tuesday, November 1 SAN DIEGO , Oct. 11, 2022 /PRNewswire/ -- Neurocrine Biosciences, In...

Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer PR Newswire SAN DIEGO , Sept. 29, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Dr. Ingrid Delaet will join the company's executi...

Wells Fargo has launched its coverage on Neurocrine Biosciences ( NASDAQ: NBIX ) with an Overweight recommendation even as the biotech, targeting treatments for neurological and psychiatric disorders, sees multiple Phase 2 readouts next year. “2023 will be a litmus ...

Summary The compelling results of endometriosis treatment MYFEMBREE's phase 3 led to the drug's approval, and Myovant will be eligible for up to $200 million based on achieving certain milestones. The endometriosis market currently has few competitors, and more generally, there ar...

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022 PR Newswire SAN DIEGO , Sept. 19, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will p...

Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress PR Newswire SAN DIEGO , Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) tod...

Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress PR Newswire SAN DIEGO , Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NB...

Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care Partners Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosci...

The biotech sector has had a challenging year so far. The SPDR S&P Biotech ETF is still down more than 26%, and the iShares Biotechnology ETF is down more than 19%, even though both have rallied a bit in the past few months. Contrast that with Vertex Pharmaceuticals (N...